Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres
Sign Up to like & getrecommendations! Published in 2021 at "Oncology Letters"
DOI: 10.3892/ol.2021.12813
Abstract: For osteosarcoma that progresses following first-line chemotherapy, prognosis remains poor although anti-angiogenesis tyrosine kinase inhibitors (TKIs) have been verified to prolong progression-free survival. Apatinib has led to positive responses in the treatment of refractory osteosarcoma.… read more here.
Keywords: relapsed refractory; iqr months; ifosfamide etoposide; refractory osteosarcoma ... See more keywords